Who Paid My Doc
Michael Klufas
Geriatric Medicine Cumberland, RI Medical Doctor
NPI 1205822277 CMS profile 327255
525 Broad St, Suite 103, Cumberland, RI 02864
General payments
$37,151
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael Klufas of Cumberland, RI is reported in the CMS Open Payments database as having received $37,151 across 1,749 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,672 | 204 | |
| 2024 | General | $5,541 | 233 | |
| 2023 | General | $6,503 | 267 | |
| 2022 | General | $5,579 | 232 | |
| 2021 | General | $7,550 | 365 | |
| 2020 | General | $3,559 | 214 | |
| 2019 | General | $3,745 | 234 |
Beside peers
- Michael Klufas
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Michael Klufas were reported at $4,672. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.
Show as a table
| Year | Michael Klufas | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,745 | $122 | $40–$435 | $163 |
| 2020 | $3,559 | $98 | $25–$349 | $114 |
| 2021 | $7,550 | $125 | $34–$441 | $132 |
| 2022 | $5,579 | $124 | $36–$408 | $149 |
| 2023 | $6,503 | $121 | $41–$383 | $160 |
| 2024 | $5,541 | $134 | $41–$435 | $164 |
| 2025 | $4,672 | $123 | $35–$408 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 318 drugsPart D claims
37,216
Drug cost
$3,284,953
Branded share of claims
21.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 1,089 | $379,673 | |
| Trulicity Dulaglutide | Brand | 267 | $256,110 | |
| Ingrezza Valbenazine Tosylate | Brand | 52 | $221,980 | |
| Jardiance Empagliflozin | Brand | 315 | $169,529 | |
| Ozempic Semaglutide | Brand | 163 | $166,729 | |
| Invega Sustenna Paliperidone Palmitate | Brand | 57 | $160,547 | |
| Invega Trinza Paliperidone Palmitate | Brand | 11 | $106,292 | |
| Xarelto Rivaroxaban | Brand | 280 | $99,444 | |
| Xifaxan Rifaximin | Brand | 21 | $68,830 | |
| Nuplazid Pimavanserin Tartrate | Brand | 26 | $64,105 |
The 10 drugs with the highest cost, of 318 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$69,717
Medicare patients
392
Services billed
923
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 44% | |
| Depression | 39% | |
| Diabetes | 34% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 28% | |
| Atrial fibrillation | 26% | |
| Alzheimer's or dementia | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 48 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| CAPLYTA |
|
$421 | — | — |
| REXULTI |
|
$392 | 25 | — |
| FARXIGA |
|
$365 | 53 | — |
| Austedo XR |
|
$361 | — | — |
| FANAPT |
|
$331 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 48 with PatronRecords
1,749 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Geriatric Medicine in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.